You are here

Dr. Nicholas Tritos

Dr. Tritos serves as Associate Physician at MGH Neuroendocrine Unit, and Associate Professor of Medicine at Harvard Medical School. He is involved in the care of patients with complex pituitary disorders in a tertiary care center (including pituitary tumors and traumatic brain injury (TBI)), conducts clinical neuroendocrine research impacting on patient care and actively engage in teaching/education.

Dr. Tritos was nominated for the 2016 MGH/MGPO McGovern Award for clinical excellence, and has an active clinical research portfolio focused on clinical research that has been innovating patient care. He has focused on the physiologic role of growth hormone (GH) in adults with hypopituitarism. He has led an international collaboration of researchers, resulting in several publications in highly cited journals. This particular work identified predictors of bone mineral density in hypopituitary adults and established gender-dimorphic effects of GH replacement on bone mineral density in this population, allowing to further characterize the role of GH on bone. He has published a study of bone microarchitecture in patients with either GH excess or deficiency. These studies have elucidated abnormalities in bone microarchitecture in patients with GH excess, who may have normal bone density, yet whose abnormal microarchitecture places them at increased fracture risk.

While leading an international research collaboration, Dr. Tritos has also published a study of the effects of GH replacement in adults with cured acromegaly. This work identified relevant benefits of GH replacement but also raised concerns about the long-term cardiovascular safety of GH replacement in this population.

He has published a study which identified predictors of hypopituitarism in patients with TBI, and has conducted meta-analyses on the effects of GH in several disease states, including effects of GH administration on bone mineral density in hypopituitarism or age-related osteoporosis, effects of GH therapy in Prader-Willi syndrome, non-syndromic obesity and congestive heart failure.

In other studies, Dr. Tritos characterized the phenotype of patients with pituitary adenomas showing thyrotropin immunoreactivity, expanding the spectrum of clinical and pathological findings in this population.

He has identified late night salivary cortisol as a sensitive marker for remission and recurrence in Cushing’s disease and studied the diagnostic sensitivity of this test in patients with cyclic Cushing’s disease.

He has introduced image texture analysis as a helpful prognostic tool in patients with pituitary adenomas.

Dr. Tritos has been committed to teaching and education; has served on the Curriculum Committee at Tufts University School of Medicine, currently serves as Chair of the Endocrine Fellowship Curriculum Committee, is a member of the Clinical Competency Committee at MGH, a Subspecialty Core Educator for Endocrinology, and the director of the neuroendocrine elective for MGH medical residents.

At a national/international level, Dr. Tritos has been serving as a member of the Endocrine Society steering group for the in-service endocrine fellowship training examination, the AACE Neuroendocrine and Pituitary Scientific Committee and Associate Editor of the Journals “Endocrine Practice” and “AACE Clinical Case Reports” for pituitary topics.

In summary, he is a neuroendocrinologist with an active clinical practice and a commitment to clinical research that has been leading to advances in patient care, teaching and education.